Summary

"The genome editing marketis valued at USD 3.5 billion in 2023 growing at a CAGR of 12.6% during the forecast period 2023-2035.
Gene editing or gene replacement is the process of modifying (inserting, deleting or replacing) a single gene (or a sequence of genes) in the genome of a living organism. In recent years, the need to edit at a specific site within the genome has increased, there has been a surge in the development of different types of genome editing tools by gene-editing companies. These include ZFNs (zinc finger nucleases), TALENs (tissue-aliphatic-like-effector nucleases) and, most recently, CRISPR (cRNA-based technology). These gene-editing tools have been widely used as a corrective strategy to treat clinical conditions resulting from genetic abnormalities, including Sickle cell disease (SCD), Parkinson's disease (PDD), hearing loss (HELP), peripheral artery disease (PAD), spinal muscular atrophies (SMA), autoimmune diseases (AML) and other types of genetic disorders. In the midst of the current efforts to create targeted gene-editing therapies, there are more than 300 candidates for gene therapy in clinical trials as of 2023. It is worth mentioning, prophylaxis treatment is another segment that has attracted a lot of attention in the market of gene editing applications. However, it is important to note that the development of a gene edited drug product involves a significant investment in the development of drugs in the field of gene research. In order to deliver these drugs efficiently, precisely and safely, the pharma companies are relying on new genome editing technologies developed by the genome editing companies, which in turn will help the drug developers in improving the clinical outcome by achieving the required genetic manipulation. With encouraging clinical trial results and accelerated drug approval, the market for genome editing is expected to experience significant growth over the next few years.



Key Market Segments
Type of Gene Editing Technique
CRISPR-Cas System
TALENs
Meganucleases
ZFNs
Other Techniques
Type of Therapy
Cell Therapies
Gene Therapies
Other Therapies
Gene Editing Approach
Gene Knock-Out Approaches
Gene Knock- In Approaches
Gene Delivery Method
Ex-Vivo Delivery Methods
In-Vivo Delivery Methods
Gene Delivery Modality
Viral Vectors
Non-Viral Vectors
Application Area
Drug Discovery and Development
Diagnostics
Type of End User
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Key Geographical Regions
North America
Europe
Asia-Pacific
Payment Method Employed
Upfront Payments
Milestone Payments

Research Coverage:
The report studies the genome editing market based on type of gene editing technique, type of therapy, gene editing approach, gene delivery method, gene delivery modality, application area, type of end user, key geographical regions and payment method employed.
The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
The report forecasts the revenue of market segments with respect to three major regions
The report includes a brief introduction to genome editing, including the evolution of the domain over the years, a list of the different genome editing technologies, and an overview of how genome editing is being used in different industries such as biotechnology, pharma and agriculture. It also highlights the various cutting-edge genome editing technologies.
Comprehensive analysis of the current technology landscape for genome editing domain considering parameters such as type of gene editing technique (CRISPR-Cas system, meganucleases, TALENs, ZFNs and other techniques), gene editing approach, type of gene delivery method, type of gene delivery modality, highest phase of drug development supported, therapeutic area and application. In addition, the chapter features information on various technology developers, along with analysis based on multiple parameters, establishment year, company size, headquarters and operational model
Create detailed profiles of leading genome editing companies, including establishment year, employees, HQ location, key executives, technology portfolios, recent developments, and future outlook.
Detailed company competitiveness evaluation of medical aesthetics company, considering developer strength and technology strength in terms of type of gene editing technique, gene editing approach, in-silico (CADD) analysis, type of gene delivery method, type of gene delivery modality, highest phase of development supported and application area.
Examine partnerships (licensing agreements, research and development agreements, technology integration agreements, etc.) in the genome editing market from 2018-2023. Analyze recent investments (grants, funding rounds) and initiatives by market stakeholders.
Review patents related to genome editing from 2018-2023, highlighting types, publication years, locations, CPC symbols, focus areas, applicant types, and leading players.
The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth

Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the genome editing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies
Arcturus Therapeutics
Avectas
Beam Therapeutics
Bio-Sourcing
Caribou Biosciences
Century Therapeutics
CRISPR Therapeutics
EdiGene
Editas Medicine
Flash Therapeutics
Fortgen
G+FLAS Life Sciences
Graphite Bio
Intellia Therapeutics
Ntrans Technologies
OXGENE
Prime Medicine
Revvity (formerly known as Horizon Discovery)
TargetGene Biotechnologies
Vor Biopharma
ZeClinics"

ページTOPに戻る

Table of Contents

"1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past
Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Introduction to Genome Editing
5.2.1. Evolution of Genome Editing
5.2.2. Genome Editing Technologies
5.2.2.1. CRISPR - Cas System
5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
5.2.2.3. Zinc Finger Nucleases (ZFNs)
5.2.2.4. Meganucleases / Homing Endonucleases

5.3. Applications of Genome Editing Technologies
5.4. Other Emerging Technologies
5.5. Concluding Remarks

6. TECHNOLOGY LANDSCAPE
6.1. Chapter Overview
6.2. Genome Editing: Technology Landscape
6.2.1. Analysis by Type of Gene Editing Technique
6.2.2. Analysis by Gene Editing Approach
6.2.3. Analysis by Type of Gene Delivery Method
6.2.4. Analysis by Type of Gene Delivery Modality
6.2.5. Analysis by Highest Phase of Drug Development Supported
6.2.6. Analysis by Therapeutic Area
6.2.7. Analysis by Application Area

6.3. Genome Editing: Technology Developer Landscape
6.3.1. Analysis by Year of Establishment

6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Operational Model
6.3.5. Most Active Players: Distribution by Number of Technologies

7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Technology Competitiveness Analysis
7.4.1. Genome Editing Technologies Offered by Players based in North America
7.4.2. Genome Editing Technologies Offered by Players based in Europe
7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Arcturus Therapeutics
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Technology Portfolio
8.2.4. Recent Developments and Future Outlook

8.3. Beam Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Technology Portfolio
8.3.4. Recent Developments and Future Outlook

8.4. Caribou Biosciences
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Technology Portfolio
8.4.4. Recent Developments and Future Outlook

8.5. Century Therapeutics
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Technology Portfolio
8.5.4. Recent Developments and Future Outlook

8.6. CRISPR Therapeutics
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Technology Portfolio
8.6.4. Recent Developments and Future Outlook

8.7. Editas Medicine
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Technology Portfolio
8.7.4. Recent Developments and Future Outlook

8.8. Graphite Bio
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Recent Developments and Future Outlook

8.9. Intellia Therapeutics
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Technology Portfolio
8.9.4. Recent Developments and Future Outlook

8.10. Prime Medicine
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Recent Developments and Future Outlook

8.11. Vor Biopharma
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Recent Developments and Future Outlook

8.12. Other Leading Players
8.12.1. Avectas
8.12.2. Bio-Sourcing
8.12.3. Edigene
8.12.4. Flash Therapeutics
8.12.5. Fortgen
8.12.6. G+FLAS Life Sciences
8.12.7. Ntrans Technologies
8.12.8. OXGENE
8.12.9. Revvity (formerly known as Horizon Discovery)
8.12.10. TargetGene Biotechnologies
8.12.11. ZeClinics

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Genome Editing Technologies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.7.1. Local and International Agreements
9.3.7.2. Intercontinental and Intracontinental Agreements

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Genome Editing Domain: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Type of Patent and Publication Year
10.3.3. Analysis by Geography
10.3.4. Analysis by CPC Symbols
10.3.5. Leading Industry Players: Analysis by Number of Patents

10.4. Genome Editing Domain: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Leading Industry Players

10.5. Patent Valuation Analysis

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Genome Editing Domain: Funding and Investment Analysis
11.3.1. Analysis by Year of Investment
11.3.1.1. Cumulative Year-wise Trend of Funding Instances
11.3.1.2. Cumulative Year-wise Trend of Amount Invested

11.3.2. Analysis by Type of Funding
11.3.2.1. Analysis of Funding Instances
11.3.2.2. Analysis of Amount Invested
11.3.3. Analysis by Year and Type of Funding
11.3.4. Analysis by Geography
11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
11.3.6. Leading Investors: Analysis by Number of Funding Instances

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion

13. GENOME EDITING TECHNOLOGIES MARKET
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
13.3.1. Scenario Analysis

13.4. Key Market Segmentations
13.5. Dynamic Dashboard

14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
14.4. TALENs: Forecasted Estimates (2023-2035)
14.5. Meganucleases: Forecasted Estimates (2023-2035)
14.6. ZFNs: Forecasted Estimates (2023-2035)
14.7. Other Techniques: Forecasted Estimates (2023-2035)
14.8. Data Triangulation
14.8.1. Insights from Primary Research
14.8.2. Insights from Secondary Research
14.8.3. Insights from In-house Repository

15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Cell Therapies: Forecasted Estimates (2023-2035)
15.4. Gene Therapies: Forecasted Estimates (2023-2035)
15.5. Other Therapies: Forecasted Estimates (2023-2035)
15.6. Data Triangulation
15.6.1. Insights from Primary Research
15.6.2. Insights from Secondary Research
15.6.3. Insights from In-house Repository

16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
16.5. Data Triangulation
16.5.1. Insights from Primary Research
16.5.2. Insights from Secondary Research
16.5.3. Insights from In-house Repository

17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.5. Data Triangulation
17.5.1. Insights from Primary Research
17.5.2. Insights from Secondary Research
17.5.3. Insights from In-house Repository

18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Viral Vectors: Forecasted Estimates (2023-2035)
18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
18.5. Data Triangulation
18.5.1. Insights from Primary Research
18.5.2. Insights from Secondary Research
18.5.3. Insights from In-house Repository

19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
19.4. Diagnostics: Forecasted Estimates (2023-2035)
19.5. Data Triangulation
19.5.1. Insights from Primary Research
19.5.2. Insights from Secondary Research
19.5.3. Insights from In-house Repository

20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
20.5. Data Triangulation
20.5.1. Insights from Primary Research
20.5.2. Insights from Secondary Research
20.5.3. Insights from In-house Repository

21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Forecasted Estimates (2023-2035)
21.4. Europe: Forecasted Estimates (2023-2035)
21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
21.6. Data Triangulation
21.6.1. Insights from Primary Research
21.6.2. Insights from Secondary Research
21.6.3. Insights from In-house Repository

22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Milestone Payments: Forecasted Estimates (2023-2035)
22.4. Upfront Payments: Forecasted Estimates (2023-2035)
22.5. Data Triangulation
22.5.1. Insights from Primary Research
22.5.2. Insights from Secondary Research
22.5.3. Insights from In-house Repository

23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS
23.1. Chapter Overview
23.2. Leading Industry Players

24. CONCLUSION

25. EXECUTIVE INSIGHTS

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS"